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Abstract
Background: Knowledge of therapy-induced intestinal tract concentrations of antimicrobials allows for
interpretation and prediction of antimicrobial resistance selection within the intestinal microbiota. This study
describes the impact of three different doses of enrofloxacin (ENR) and two different administration routes on the
intestinal concentration of ENR and on the fecal Escherichia coli populations in pigs. Enrofloxacin was administered
on three consecutive days to four different treatment groups. The groups either received an oral bolus
administration of ENR (conventional or half dose) or an intramuscular administration (conventional or double dose).
Results: Quantitative analysis of fecal samples showed high ENR concentrations in all groups, ranging from 5.114 ±
1.272 μg/g up to 39.54 ± 10.43 μg/g at the end of the treatment period. In addition, analysis of the luminal intestinal
content revealed an increase of ENR concentration from the proximal to the distal intestinal tract segments, with
no significant effect of administration route. Fecal samples were also screened for resistance in E. coli isolates
against ENR. Wild-type (MIC≤0.125 μg/mL) and non-wild-type (0.125 < MIC≤2 μg/mL) E. coli isolates were found at
time 0 h. At the end of treatment (3 days) only non-wild-type isolates (MIC≥32 μg/mL) were found.
Conclusions: In conclusion, the observed intestinal ENR concentrations in all groups showed to be both
theoretically (based on pharmacokinetic and pharmacodynamic principles) and effectively (in vivo measurement)
capable of significantly reducing the intestinal E. coli wild-type population.
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Background
Antimicrobial drugs are essential to treat clinical bacter-
ial infectious diseases in both human and veterinary
medicine. However, the extensive use of antimicrobials
has led to an increase in antimicrobial resistance (AMR)
[1]. A direct relation has been described between the use
of antimicrobials and subsequent antimicrobial resist-
ance [2–4]. Antimicrobial therapy does not only affect
the targeted pathogen but also the commensal bacteria.
Therefore, the gut microbiota is considered as a poten-
tial reservoir of resistance genes [5, 6]. The formation
and selection of resistant strains in the gut commensal
microbiota can facilitate the environmental spread of re-
sistance genes and resistant bacteria [7]. This type of
spread poses a significant risk for the animal to human
resistance transfer and vice versa [8], pointing towards
the need for a ‘One Health’ approach.
The currently marketed antimicrobials lack data on in-
testinal exposure. However, this exposure could have an
effect on the formation or selection of resistant bacteria in
the gut. Furthermore, limited information is available on
the impact of the administration route and dose. Since
parenteral administration does not require absorption
from the gut, parenteral administration is generally
deemed to have less influence on the gut microbiota com-
pared with oral administration. For oral administration it
has been demonstrated that incomplete absorption leads
to gastro-intestinal drug residues which can affect the
microbiota. However, not only incomplete absorption can
cause intestinal exposure. Excretion of antimicrobials from
blood to gut lumen can occur and is independent of ad-
ministration route. Therefore, it is important to map the
excretion mechanisms for specific molecules [9]. As previ-
ously reported, this excretion process is drug dependent
[10]. In our previous study, sulfadiazine-trimethoprim was
administered orally (PO) and intramuscularly (IM) to pigs
and it was observed that sulfadiazine accumulated in distal
gut segments and feces whilst trimethoprim displayed the
exact opposite concentration pattern [10]. This accumula-
tion was irrespective of the administration route. Peeters
et al. [11] also observed a similar accumulation towards
distal gastro-intestinal segments for tetracyclines after
feeding cross-contamination levels of chlortetracycline
and doxycycline to pigs.
Enrofloxacin (ENR) was selected as antimicrobial of
interest to this study. It is a second-generation fluoro-
quinolone (FQ) and a structural analogue of ciprofloxacin
(CIP), which is used in human medicine. ENR is adminis-
tered to pigs for treatment of respiratory tract infections
(e.g. Pasteurella multocida and Actinobacillus pleuropneu-
moniae) but it is also licensed (Federal Agency for Medi-
cines and Health Products (FAMHP) of Belgium) to treat
gastro-intestinal infections, e.g. caused by E. coli. The
main purpose of this study was to elucidate the impact of
the administration route on the intestinal concentrations
of ENR in pigs. The other purpose was to assess the effect
of these ENR intestinal concentrations on the coliform
microbiota. Previously, it has been demonstrated that the
FQ antimicrobials have a detrimental effect on the Gram-
negative aerobic microbiota [12]. Römer et al. demon-
strated that parenteral administration of ENR in piglets
caused a considerable reduction of the susceptible intes-
tinal E. coli population, in favor of resistant E. coli isolates
[13]. Wiuff et al. also demonstrated a rapid development
of resistance in coliforms in the gut of pigs after PO or IM
administration of ENR [14]. However, no further pharma-
codynamic (PD) and bacteriological investigation was exe-
cuted. Therefore, it remains unclear whether the
administration route and altered ENR dose could have an
influence on resistance in the commensal microbiota and
how this antimicrobial resistance is characterized.
In the current study, the effect of the administration
route (PO or IM) on intestinal ENR concentrations was
evaluated in pigs. Intestinal exposure can be related to in-
complete gastro-intestinal uptake after oral administration
(oral bioavailability) or to systemic intestinal excretion.
Minimal dosing discrepancies were administered in order
to simulate a possible in-field situation for the IM admin-
istrations. These dosing discrepancies were based on a
publication by Callens et al. [15] after a survey of 50 differ-
ent Belgian pig farms. This survey reported that oral anti-
microbial treatment in pigs was often under-dosed, whilst
IM treatment was mostly over-dosed. In Belgium, only IM
administration of ENR is licensed for use in pigs (FAMH
P). Oral administration of ENR was only evaluated to
allow for a comparison with IM administration and to as-
sess differences in intestinal exposure between oral and
parental administration. From a One Health perspective,
oral administration could also provide information when
considering the pig as a model for human pharmacokinet-
ics [16], since in human healthcare ciprofloxacin is also
administered orally (tablets) and parenterally (intraven-
ously). The main aim of this study was to determine the
linearity of the ENR concentration in the different intes-
tinal tract segments after oral or intramuscular adminis-
tration of ENR at different doses. Secondarily, fecal
samples were collected on different time points during
treatment. The antimicrobial susceptibility of randomly
collected E. coli isolates of these samples was examined.
This experiment allowed for an evaluation of the impact
of different ENR routes of administration (i.e. oral versus
intramuscular) and doses on E. coli resistance selection in
the porcine fecal microbiota.
Results
LC-MS/MS method validation
The results of the different validation parameters are
given in supplementary Table B1 and B2 and fulfilled all
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criteria as described by the Veterinary International
Conference of Harmonization (VICH, guideline 49 [17])
and the European Commission directives concerning the
performance of analytical methods and interpretation
[18]. The LC-MS/MS analytical method was based on a
study using similar LC-MS/MS parameters for the deter-
mination of ENR in biological samples [19].
Plasma, intestinal and fecal enrofloxacin concentrations
The plasma concentrations-time profiles of ENR for all
treatment groups are displayed in Fig. 1. The PK param-
eters are given in Table 1 and were comparable to those
in earlier studies of ENR in pigs [14, 20]. The AUC0–24h
values after one administration and AUC0–58h values
after a 3-day treatment period were compared between
the different treatment groups (Table 1).
An overview of the average intestinal ENR concentra-
tion in six different gut segments is given in Fig. 2. The
ENR concentration tends to increase towards the distal
segments. A more than two-fold increase in concentra-
tion from jejunum to colon was observed in every treat-
ment group. This observation was independent of the
administration route (PO or IM).
In Fig. 2a, the average fecal concentrations of ENR for the
different treatment groups are depicted. These were sam-
pled twice daily during the 3-day treatment period. High
Fig. 1 Plasma concentrations after the first administration of enrofloxacin (ENR) to pigs (n = 6 per group) and further during the three-day
treatment period. Results are presented as mean + SD. With group 1(oral bolus) and 3 (IM): conventional dose: 2.5 mg/kg BW (1x daily); group 2
(oral bolus): half dose: 1.25 mg/kg BW (1x daily); group 4 (IM): double dose: 5 mg/kg BW (1x daily)
Table 1 Overview of the pharmacokinetic (PK) parameters in plasma
PK parameters Group 1
PO
2.5mg ENR/ kg BW
Group 2
PO
1.25mg ENR/ kg BW
Group 3
IM
2.5mg ENR/ kg BW
Group 4
IM
5mg ENR/ kg BW
Cmax (μg/mL) 0.45 ± 0.080a 0.18 ± 0.017b 0.57 ± 0.14a 1.02 ± 0.15c
Tmax (h) 2.25 ± 1.48
a 2.00 ± 0.63a 2.50 ± 0.84a 4.00 ± 2.10a
AUC0–24 h (h*μg/mL) 5.93 ± 1.16a 2.02 ± 0.18b 6.88 ± 1.93a 12.26 ± 1.83c
AUC0–58 h (h*μg/mL) 14.98 ± 2.13a 6.08 ± 1.40b 16.13 ± 3.87a 28.50 ± 3.65c
AUC0–58 h/D 8.96 10
− 4 ±
4.63 10− 4 a
8.54 10− 4 ±
6.66 10− 4 a
8.59 10− 4 ±
3.81 10− 4 a
8.18 10− 4 ±
2.45 10− 4 a
Cpss (μg/mL) 0.25 ± 0.049a 0.092 ± 0.021b 0.29 ± 0.081a 0.51 ± 0.076c
Overview of the area under the curve from 0 to 24 h (AUC0–24 h), maximal plasma concentration of ENR (Cmax), and time of Cmax (Tmax) for groups 1, 2, 3 and
4 after the first administration (0–24 h). Also, the AUC0–58 h values (3 treatment days days), AUC0–58 h values normalized for dose (D) administered (AUC0–58 h/
D) and the steady state plasma concentrations (Cpss) for groups 1, 2, 3 and 4 are given. A difference in superscripts a, b or c denotes a statistical significant
difference between these groups. Statistics were exerted using a single-factor ANOVA with a post-hoc Tukey test (equality of variances checked), significance level
0.05. For AUC0–58h/D an independent-samples T test was used to compare the mean values between group 1–2 and 3–4
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Fig. 2 a: Enrofloxacin (ENR) concentrations in feces, collected during 3 days of treatment (sampling at 0, 10, 24, 34, 48 h and 58 h). With oral
bolus administration in group 1 (n = 6): conventional: 2.5 mg/kg BW (1x daily); group 2 (n = 6): half dose: 1.25 mg/kg BW (1x daily); and IM
administrations in group 3 (n = 6): conventional: 2.5 mg/kg BW (1x daily); group 4 (n = 6): double dose: 5 mg/kg BW (1x daily). b: ENR
concentrations in the different gastro-intestinal segments: duodenum, jejunum, ileum, cecum, colon and feces. Sampling was performed 10 h
after the final ENR administration (time point 58 h) in each treatment group. ↓ marking means no SD was presented because of the lack of
sufficient data (either insufficient intestinal sample collection or values not quantifiable)
Table 2 Overview of the fecal pharmacokinetic (PK) parameters
PK parameters Group 1
PO
2.5mg ENR/ kg BW
Group 2
PO
1.25mg ENR/ kg BW
Group 3
IM
2.5 mg ENR/ kg BW
Group 4
IM
5mg ENR/ kg BW
Cmax (μg/g) 17.75 ± 3.64a 5.11 ± 1.27b 15.00 ± 4.01a 24.14 ± 4.48c
Cmax/D 2.94 10
− 4 ±
1.59 10− 4 a
2.6110− 4 ±
7.42 10− 5 a
3.67 10−4 ±
1.07 10− 4 a
2.97 10− 4 ±
1.17 10− 4 a
Cmin (μg/g) 6.53 ± 4.96a 4.32 ± 1.51a 5.21 ± 4.97a 7.92 ± 4.01a
AUC0–58hfeces
(h*μg/g)
775.93 ± 217.80a 299.34 ± 55.55b 808.01 ± 122.33a 1469.61 ± 502.00c
Cssfeces (μg/g) 12.94 ± 0.55
a 4.51 ± 1.28b 10.64 ± 2.32a 19.53 ± 11.96c
Overview of the area under the curve from 0 to 58 h (AUC0–58 h) for fecal concentrations, maximal and minimal fecal concentrations (Cmax and Cmin) and
average steady state fecal concentrations (Cpssfecal) for groups 1, 2, 3 and 4. Linearity was checked by normalizing Cmax for dose (D) administered (Cmax/D). A
difference in superscripts a, b or c denotes a statistical significant difference between these groups. Statistics were exerted using a single-factor ANOVA with a
post-hoc Tukey test (equal variances checked), significance level 0.05. For Cmax/D an independent-samples T test was used to compare the mean values between
group 1–2 and 3–4
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fecal concentrations (ranging between 7.77 ± 2.24 μg/g and
39.54 ± 10.43 μg/g) were measured in every treatment
group.
An overview of the calculated PK parameters based on
the fecal concentrations is given in Table 2. No signifi-
cant differences in AUC0–58h feces values were found for
group 1 and 3 (same dose, different administration
route).
Bacteriology
All selected isolates with score values of ≥2.300 after
MALDI TOF-MS analysis were confirmed as E. coli. The
majority (≥98%) of the investigated E. coli population at
time point 0 h belonged to the wild-type (WT) popula-
tion concerning ENR antimicrobial susceptibility. The
magnitude of wild-type colony counts was in all treat-
ment groups between 3-4 × 104 CFU/g on MC agar. The
median MIC was 0.023 μg/mL for group 1, 2 and 3 and
0.016 μg/mL for group 4. A minor (≤2%) non-wild type
E. coli population was present in some animals at the
start of the experiment (1 to 3 animals per group in the
different treatment groups). The magnitude of the non-
wild type colony counts was between 1-8 × 102 CFU/g
on MC agar + 0.125 μg/mL ENR. The median MIC was
1 μg/mL for group 1 and 2, 0.5 μg/mL for group 3 and
0.75 μg/mL for group 4. These isolates showed MIC
values above the WT cut-off value, consistent with ac-
quired ENR resistance mechanisms (0.5 μg/mL ≤MIC≤2
μg/mL). At the end of the treatment (58 h), only a very
low number of E. coli isolates was retrieved from the
samples and the CFU count magnitude had dropped to
≤101 CFU/g. Moreover, all of these isolates showed ENR
MIC values of ≥32 μg/mL (32 μg/mL is the upper limit
of the gradient test strip). An overview of the results ob-
tained by sequencing the gyrA and parC genes for sev-
eral wild-type (retrieved at 0 h), non-wild type (retrieved
at 0 h) and all non-wild-type (retrieved at 58 h) isolates
is given in Table 3. All non-wild type isolates collected
at time point 0 h, carried silent mutations in gyrA
(85GTT, 91CGT, 100TAC, 110TCC) and parC
(91CAG). These isolates were also positive for the
plasmid-mediated qnrS1 resistance gene [21], whereas
the wild-type (retrieved at 0 h) and the non-wild type
(retrieved at 58 h) isolates were negative for all investi-
gated qnr genes.
Next, all isolates were genotyped by (rep)-PCR as indi-
cated in Fig. 3. The wild-type isolates (MIC≤0.125 μg/
mL) that were tested, all belonged to genotype C. The
Table 3 Results of the gene mutations of gyrA and parC for selected strains from the different treatment groups, the minimal
inhibitory concentration (MIC) values are also provided for these isolates with wild-type cut-off of 0.125 μg/mL. The silent mutations,
i.e. polymorphisms in codon sequence resulting in the same amino acid, in gyrA and parC are given, with the reference sequences
indicated in grey. Escherichia coli K12 MG1655 was used for reference
Isolate MIC (μg/mL) gyrA mutations parC mutations Silent mutations (gyrA/ parC) and additional resistance
mechanisms
E. coli K12 MG1655 NA None None REFERENCE gyrA: 85GTC, 91CGC, 100TAT, 110TCT /parC: 91CAA
ATCC 25922™ 0.064 None None
Y01.V2 – Group 1 – 0 h 0.064 None None
Y08.V3 – Group 2 – 0 h 0.032 None None
Y11.V2 – Group 3 – 0 h 0.016 None None
Y12.V2 – Group 4 – 0 h 0.064 None None
X02.V2 – Group 1 – 0 h 2.00 None None gyrA: 85GTT, 91CGT, 100TAC, 110TCC/ parC: 91CAG and qnrS1 positive
Y02.V2 – Group 2 – 0 h 4.00 None None gyrA: 85GTT, 91CGT, 100TAC, 110TCC/ parC: 91CAG and qnrS1 positive
X06.V2 – Group 2 – 0 h 4.00 None None gyrA: 85GTT, 91CGT, 100TAC, 110TCC/ parC: 91CAG and qnrS1 positive
Y09.V2 – Group 3 – 0 h 2.00 None None gyrA: 85GTT, 91CGT, 100TAC, 110TCC/ parC: 91CAG and qnrS1 positive
X12.V2 – Group 4 – 0 h 1.00 None None gyrA: 85GTT, 91CGT, 100TAC, 110TCC/ parC: 91CAG and qnrS1 positive
X04.V2 – Group 1 – 58 h > 32.00 83Leu, 87Asn 80Ile
X07.V3 – Group 2 – 58 h > 32.00 None None
X08.V4 – Group 2 – 58 h > 32.00 83Leu, 87Asn 80Ile
X09. V4 – Group 2 – 58 h > 32.00 83Leu, 87Asn 80Ile
X11.V6 – Group 3 – 58 h > 32.00 83Leu, 87Asn 80Ile
X13.V1 – Group 4 – 58 h > 32.00 83Leu, 87Asn 80Ile
X14.V1 – Group 4 – 58 h > 32.00 83Leu, 87Asn 80Ile
X15. V1 – Group 4 – 58 h > 32.00 83Leu, 87Asn 80Ile
NA Not available
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non-wild type isolates (1 μg/mL ≤MIC≤4 μg/mL)
belonged to genotype A with one exception that
belonged to genotype B. All non-wild type isolates with
MIC≥32 μg /mL belonged to genotype B, with one ex-
ception belonging to genotype C. None of the non-wild
type isolates with MIC≥32 μg /mL (both isolates belong-
ing to genotype B as well as C) contained the gyrA or
parC silent mutations or the qnrS1 resistance determi-
nants as observed in the non-wild type isolates retrieved
at 0 h.
Discussion
Plasma, intestinal and fecal enrofloxacin concentrations
There was no significant difference in AUC values be-
tween group 1 and 3. Both groups received the same
dose (2.5 mg ENR/kg BW) but via a different administra-
tion route (PO and IM, respectively), indicating that the
administration route had no significant influence on
plasma concentrations of ENR. This is consistent with
the report that the oral bioavailability of FQs in fasted
pigs is complete [20]. Next, linearity of the dose was
evaluated by normalizing the AUC values for the actual
administered dose (D). The calculated AUC0–58h/D
values were all in the same range within groups 1–2 (PO
administration) and 3–4 (IM administration) (Table 1).
Therefore, linear PK of ENR in plasma was assumed for
both administration routes at the investigated dose
range. After normalizing the measured fecal Cmax
values for dose, linear PK was also confirmed for ENR in
feces at the doses studied.
After conventional treatment (2.5 mg ENR/kg BW) ei-
ther PO or IM, the average concentration of ENR was
≤10 μg ENR/g jejunal contents and increased to ≥20 μg
ENR/g colonic contents with a maximum of 40.21 ±
12.49 μg/g. This increase in concentration towards the
more distal segments indicates that the intestinal con-
centration is not related to an incomplete absorption
process after PO administration. It should be noted that
the intestinal concentrations that were measured during
this study, represent a single time point (i.e. intestinal
samples were collected at 10 h after the last administra-
tion of ENR) and do not display the dynamics of ENR
movement within the GIT. Earlier work by Ferran et al.
demonstrated the dynamics of marbofloxacin in the
proximal intestinal segments, clearly demonstrating an
alteration in concentrations of the molecule within the
different GIT segments, in function of time (1.5, 2, 4, 6,
9, 12 and 24 h post-administration) [22]. However, the
magnitude of these concentrations (5 up to 30 μg/g in
the proximal segments) is comparable to the values re-
ported in this study.
The observed high fecal concentrations of ENR are in
line with the accumulating intestinal concentrations
measured at the end of treatment (Fig. 2b). Furthermore,
no significant differences (p > 0.05) in average concentra-
tions of ENR were detected between the intestinal and
fecal contents within the same treatment group. This
Fig. 3 Repetitive element sequenced-based (rep)-PCR of 17 different retrieved Escherichia coli isolates (time point 0 h and 58 h), from the 4
different treatment groups and in total from 10 different pigs. The minimal inhibitory concentration (MIC in μg/mL) was determined for each
isolate. Treatment group 1 and 2 were administered an oral bolus of either 2.5 or 1.25 mg enrofloxacin (ENR)/kg BW respectively (3
administrations), group 3 and 4 administered ENR intramuscular at 2.5 and 5mg ENR/kg BW respectively (3 administrations). Different genotypic
groups were observed. The different gel lines were re-grouped in order to sort the data per treatment group. This is also indicated in the figure
by means of clear black lines
De Smet et al. BMC Veterinary Research          (2020) 16:382 Page 6 of 12
indicates a similar concentration-related effect on the
microbiota present in the distal gut and feces. It has to
be mentioned that the measured concentrations of ENR
do not differentiate between bound and unbound frac-
tion in the feces or intestinal tract. The total amount of
the molecule was measured in this study without making
a distinction between antimicrobial active and inactive
fraction. Nonetheless, this study shows the effect of the
therapeutic strategy on the gastro-intestinal concentra-
tions of ENR and the subsequent effect of these concen-
trations on E. coli isolates from the fecal microbiota. The
goal was to compare the effect of different administra-
tion routes and doses within the same experiment. Given
this relative comparison, the determination of the free
antimicrobial fraction in the gut is less crucial.
High fecal concentrations of ENR in pigs have been re-
ported before [23, 24]. However, renal excretion of ENR
via glomerular filtration and active tubular secretion is
still often reported as the main excretion mechanism
[25]. The exact mechanisms of intestinal FQ secretion
remain unclear. Several reports have indicated active in-
testinal secretion of FQ antimicrobials either through P-
glycoprotein or cationic transporters [26–28]. Entero-
hepatic recirculation has also been described for ENR
[29]. This can lead to an additional gastro-intestinal ex-
posure. Lastly, ion trapping might also play a role in the
increase of ENR in the distal gut segments because of the
zwitterionic properties of ENR. At distal gut pH levels
(≥6) a significant amount of the molecule (pKa 5.88 and
7.70) will be negatively charged [30]. This, in combination
with the resorption of water in the distal parts of the gut,
will attribute to the accumulation of ENR.
In conclusion, in this experimental setup, intestinal
and fecal ENR concentrations are similar after oral and
intramuscular administration of the same dose (2.5 mg
ENR/ kg BW) during a three-day treatment period.
PK/PD analysis
In general the most important PK/PD indices related to
the efficacy of FQs are plasma Cmax/MIC≥10 [31] and
AUC0–24/MIC≥125 h [32]. Extensive research has shown
that these parameters correlate well with predicting the
bacterial killing efficacy [31]. The fecal Cmax values of
ENR measured during the in vivo experiment (Table 2)
indicate that at least in the distal parts of the intestines
(colon, feces) and for all currently tested treatment pro-
tocols the E. coli isolates belonging to the ENR wild type
population (MIC≤0.125 μg/mL) will be theoretically
killed (Cmax/MIC≥10).
The Cmax values from this study are based on the
quantitative analysis of ENR in feces at 0, 10, 24, 34, 48
and 58 h during the three-day treatment period. These
Cmax values can be correlated to the specific MIC value
of a bacterial isolate from the fecal microbiota. However,
fecal and intestinal samples were not assessed frequently
enough to generate an AUC from time point 0–24 h.
Therefore, the AUC0–24/MIC parameter was not used in
this study.
Bacteriology
None of the non-wild type isolates (retrieved at 58 h,
with MIC≥32 μg /mL) that belonged to genotype B con-
tained the gyrA or parC silent mutations or the qnrS1
resistance determinants. Therefore, these isolates prob-
ably did not develop out of the non-wild type isolates
(retrieved at 0 h). They may have been selected for from
a parental strain, common to both the non-wild type
genotype B isolates collected at 0 h and those collected
at 58 h. Such a parental strain was not observed at the
start of the experiment, but may have been missed, since
not all wild type isolates could be genotyped. All of the
non-wild type isolates (retrieved at 58 h) that belonged
to genotype B carried mutations in gyrA (83Leu, 87Asn)
and parC (80Ile). These mutations are associated with
FQ resistance [33]. One non-wild type isolate (retrieved
at 58 h) belonged to genotype C (X07.V3 from Table 3)
and lacked mutations in gyrA and parC. This isolate was
probably selected for out of the WT population since all
investigated WT isolates observed at time point 0 h,
belonged to genotype C. The mechanism of resistance
for this isolate is not clear and requires further investiga-
tion, possibly indicating mutations in gyrB and/or parE.
However, these mutations were not assessed during this
study, as mutations in these genes are considered less
prevalent for E. coli resistance against FQs [34]. Finally,
there is an indication for clonal spread of a single high-
resistant strain over the different treatment groups.
Since, apart from X07.V3, all isolates belonged to the
same genotype B.
The experimental setup applied in this study had some
obvious shortcomings as it could not exclude
(personnel-mediated) carry-over of genetic material be-
tween housing confinements of the treatment groups. In
addition, (rep)-PCR, used to genotype the isolates, is
known to lack sufficient reproducibility. In this context,
whole genome sequencing could result in a higher ac-
curacy and reliability. However, this technique is expen-
sive and results in a high output, whereas (rep)-PCR is
fast and inexpensive. In this study the isolates were ge-
notyped by (rep)-PCR, since it is able to determine the
genetic relatedness between the isolates. In future stud-
ies, where more detailed genotyping is needed, methods
with higher discriminatory power should be applied. An-
other shortcoming in this study is the limited sensitivity
of the applied detection method (plate enumeration).
The fecal and intestinal samples were also frozen at −
80 °C without addition of a cryopreservant. This can re-
duce the number of counts for E. coli. However, in this
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study the plate counts of the different groups were com-
pared. Therefore, absolute counts are less relevant.
Nonetheless, a similar methodology for phenotypic ana-
lysis from fecal material is exerted by other related stud-
ies (albeit with different molecules). In these studies
colony collection ranged from 3, 5 up to 20 colonies per
plate respectively [35–37]. Since in this experiment there
was no untreated control group, the accurate assessment
of potential clonal spread was not possible. Taking into
account these limitations, the presented results still indi-
cate a significant impact of ENR on the fecal microbiota.
Two studies using a similar methodology [13, 14] (i.e.
plating of pig fecal material on a selective agar base to
enumerate E. coli from the microbiota) demonstrated a
similar susceptibility shift for E. coli from the fecal
microbiota after treatment with ENR. In this context, E.
coli is considered an important indicator bacterium,
representing facultative anaerobic Gram-negative bac-
teria in the gut microbiota of animals and humans. It is
the only bacterium of the fecal microbiota that was
assessed in this study. However, in culture-based studies
E. coli provides enough evidentiary value in terms of
monitoring resistance. E. coli is also a bacterium of the
microbiota in both humans and animals, and is abun-
dant in the environment [38]. Therefore, it allows for a
general estimation of resistance spread within this spe-
cific microorganism. In conclusion, limiting a bacterio-
logical experiment to merely studying the effect in E.
coli seems justifiable as these data actually provide indi-
cative value. Nevertheless, the impact on the total micro-
biome can be different than solely based on E. coli.
At the end of the administration (58 h) only non-wild
type isolates were recovered from the fecal samples. The
presence of these non-wild type isolates is a remarkable
finding and the cause of this observation is not clear.
The fact that these isolates were not recovered at the be-
ginning of the treatment could be related to their
colonization site within the pig and because of the lim-
ited number of isolates that were fully characterized at
time point 0 h. It is possible that minor resistant subpop-
ulations were present in the mucus layers of the gut [39,
40] and were not found in the fecal samples. The com-
position of the intestinal microbiota can also differ from
the one found in feces. Therefore, it cannot be excluded
that the strain was present in the intestinal tract as a
minor population, in one or more animals at the start of
the experiment but was simply not detected until select-
ive enrichment following ENR treatment. Nonetheless,
de novo formation of these mutants cannot be excluded
either. These bacteriological results are in alignment
with the theoretical PK/PD predictions, for which a simi-
lar outcome was expected. It should be noted that these
bacteriological determinations represent the situation of
the fecal microbiota 10 h after the administration of the
last dose of a three-day treatment period. It is expected
that at this time point, the situation can be the most
drastic in terms of resistance emergence in E. coli be-
cause of the sustained antimicrobial pressure during
treatment. A post-treatment follow-up of the fecal
microbiota after cessation of treatment was not exerted
in this study. However, this could yield important results
as a reversal of the observed resistance and eradication
of fecal E. coli is likely to occur [41]. Nonetheless, in
terms of this reversibility, several factors have to be
taken into account such as fitness of the resistant mu-
tants and dilution of the treated herd [42].
Conclusions
This is the first study reporting relevant intestinal con-
centrations of ENR in pigs after both oral and parenteral
administration. Intestinal ENR concentrations gradually
increase from proximal towards distal gut segments. The
highest concentrations were observed in colon and fecal
samples. The observed intestinal ENR concentrations
after both PO and IM administration demonstrated to
be theoretically and effectively capable of reducing (i.e.
below the limit of detection) the intestinal E. coli WT
population. Further experiments are needed to deter-
mine whether dose or route of administration can influ-




The animal experiment was approved by the Ethical
Committee of the Faculties of Veterinary Medicine and
Bioscience Engineering of Ghent University (case num-
ber EC 2015–16). The experimental setup and housing
conditions were in complete accordance with the Belgian
law, as stated in the Royal Decree of the 29th of May
2013 “KB on the protection of experimental animals”.
Twenty four pigs (Belgian Landrace, 10 weeks old, mixed
sex and not exposed to previous antimicrobial treat-
ment) were obtained from Flanders Research Institute
for Agriculture, Fisheries and Food (Melle, Belgium).
The pigs were group-housed in the same stable but
within different, fully separated confinements (n = 3 per
confinement) on 50/50 concrete floor/grids and had ad
libitum access to food (Aveve NV, Melle, Belgium) and
water during the entire study. An acclimatization period
of 5 days was respected before the start of the experi-
ment. The animals had never been treated with FQ anti-
microbials before the start of the experiment. Each
group consisted of six animals, with the group as experi-
mental unit and plasma/ faecal concentration of ENR as
primary parameter. The number of animals was based
on previously obtained data.
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Baytril® 10% oral solution was used (Bayer SA-NV,
Diegem, Belgium) for the oral administrations in group
1 (average bodyweight (BW): 16.17 ± 3.19 kg) and 2
(average BW: 15.83 ± 1.17 kg). Oral administration was
done via oral gavage for 3 consecutive days, with a 24 h
interval per administration. Group 1 was administered a
dose of 2.5 mg ENR/kg BW in accordance with the leaf-
let, and group 2 was administered half the recommended
dose, namely 1.25 mg ENR/kg BW. The animals in
group 3 (average BW: 16.83 ± 2.99 kg) and 4 (average
BW: 16.33 ± 1.63 kg) received the dose of ENR via IM
administration with Baytril® 100 mg/mL (Bayer SA-NV,
Diegem, Belgium), which was also administered once
daily with a 24 h interval for 3 consecutive days, as de-
scribed by the manufacturer. Group 3 was administered
an injection of 2.5 mg ENR/kg BW in accordance with
the leaflet, and group 4 was administered a double dose
of 5 mg ENR/kg BW. An overview of the experimental
setup is given in Figure A (supplementary files). During
the first administration-day, blood samples (± 1 mL)
were collected from the jugular vein in heparin-
containing vacuum tubes (Vacutest Kima, Arzergrande,
Italy) at time points: 0, 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 h
after administration. Furthermore blood was collected
daily on the remaining treatment days; i) pre-
administration, ii) at expected time of maximal plasma
concentration (2 h) and iii) at expected trough concen-
trations (10 h post-administration). Fecal samples (± 2 g)
were collected daily; i) pre-administration and ii) 10 h
post-administration in sterile plastic cups, after rectal
stimulation. After 3 days of treatment, the animals in
each treatment group were euthanized 10 h after the last
administration (i.e. 58 h for IM groups and 106 h for oral
groups after start of dosing), with induction of
anesthesia (0.3 mg/kg BW xylazine (Xyl-M®, V.M.D. Vet,
Arendonk, Belgium) and 15 mg/kg BW tiletamine-
zolazepam (Zoletil 100®, Virbac, Barneveld, the
Netherlands)) followed by intra-cardiac injection of so-
dium pentobarbital 20% (Kela Veterinaria, Sint-Niklaas,
Belgium). Next, intestinal content (± 2 g whenever pos-
sible) was collected from different gut segments (duode-
num, mid-jejunum, ileum, cecum, mid-colon and
rectum). Blood samples were centrifuged (2851 x g, 10
min, 4 °C) and plasma was separated and stored at ≤ −
15 °C within 2 h after collection. Fecal samples and intes-
tinal content were stored at ≤ − 80 °C within 2 h after
collection.
LC-MS/MS analysis of ENR in plasma and intestinal
content
Chemicals and reagents
All solvents used were of analytical grade; acetonitrile
(ACN), methanol (MeOH), water (H2O) from Fisher Sci-
entific (Erembodegem, Belgium), glacial acetic acid and
ethyl acetate from VWR (Leuven, Belgium). Standards of
ENR and internal standard (IS) ENR-d5 were purchased
from Sigma-Aldrich (Diegem, Belgium) and prepared in
a H2O/MeOH solution (50/50 v/v). These stock solu-
tions of 1 mg/mL were stored airtight and protected
from light at ≤ − 15 °C for a maximal period of 60 days.
Phosphate-buffered saline (PBS) was purchased from
Sigma-Aldrich (Diegem, Belgium).
Sample preparation
The sample preparation for plasma, fecal and intestinal
samples was very similar. For all fecal and intestinal
samples, one gram of sample was weighed for further
quantitative analysis. These samples were diluted 10-fold
(weight based) in PBS. The fecal and intestinal samples
were spiked with 25.0 μL of the IS solution (40 μg/mL
ENR-d5 in 50/50 (v/v) H2O/MeOH). After liquid-liquid
extraction with ethyl acetate and a horizontal shaker (10
min), all samples were evaporated to dryness at 40 ± 2 °C
with nitrogen. The extract was reconstituted using
500.0 μL of a H2O/ACN (80/20 v/v) mixture. Finally, the
samples were transferred to a glass vial after filtering
through 0.45-μm nylon filters (Merck Millipore, Over-
ijse, Belgium). An aliquot of 10.0 μL was injected onto
the liquid chromatography-tandem mass spectrometry
(LC-MS/MS) instrument. For the plasma samples,
250 μL of plasma was spiked with 12.5 μL of the IS solu-
tion (10 μg/mL ENR-d5 in 50/50 (v/v) H2O/MeOH), ex-
tracted with ethyl acetate (shaken for 10 min) and
evaporated to dryness under nitrogen flow 40 ± 2 °C.
The samples were reconstituted with 250.0 μL of a H2O/
ACN (80/20 v/v) mixture. Again, an aliquot of 10.0 μL
was injected onto the LC-MS/MS instrument.
LC-MS/MS analysis
For liquid chromatography a Zorbax Eclipse Plus col-
umn (Reversed Phase C18, 100 mm × 30mm i.d., dp:
3.5 μm) in combination with a guard column (13 mm ×
3mm i.d., dp: 3.5 μm) was used (Agilent Technologies,
Diegem, Belgium). Mobile phases and gradient elution
for chromatographic separation are given in supplemen-
tary Table A1. The LC effluent was coupled to a Thermo
Fisher Scientific TSQ® Quantum Ultra (Breda, The
Netherlands) triple quadrupole mass spectrometer with
ion source heated electrospray ionization (ESI) operating
in positive ionization mode. Acquisition was performed
in the selected reaction monitoring (SRM) mode. For
ENR and IS, the following transitions were followed
(*quantification ion): ENR: m/z 360.0 > 316.07, 244.74*
and ENR-d5: m/z 365.0 > 321.11, 244.81*. Further details
of the instrumentation parameters are given in supple-
mentary Table A2. The methods used for quantification
of ENR in this study were validated using matrix-
matched calibrator and quality control samples. These
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were based on blank plasma and fecal samples originat-
ing from untreated pigs. The method validation was
based on an in-house developed validation protocol as
described by De Baere et al. [43].
Isolation, quantification and characterization of E.coli
strains from faeces
For bacteriological investigations, fecal samples from
each animal were examined. The samples were obtained
at the beginning of the experiment just before treatment
(0 h) and 10 h after the last administration of ENR (58
h). These fecal samples (1 g weighed) were thawed from
≤ − 80 °C and diluted 10-fold (weight-based) in sterile
PBS. Next, 40.0 μL of this dilution was plated onto i)
MacConkey (MC) agar n° 3 (Oxoid NV, Erembodegem,
Belgium) and ii) MC agar supplemented with 0.125 μg/
mL ENR (EUCAST epidemiological cut-off (ECOFF)).
Spiral plating was performed with an Eddy Jet spiral
plater (IUL S.A., Barcelona, Spain) to enumerate the col-
onies. Subsequently, the agar plates were aerobically in-
cubated at 35 ± 2 °C for 20–24 h. Total plate count was
measured by manual count on both sets of plates. Plate
counts were performed on the dilutions that resulted in
a colony density of 20–300 colonies per plate [44]. Only
regular-shaped, large lactose positive (pink) colonies
were provisionally identified as E. coli and were counted.
Up to 5 colonies (when available) per plate were purified
and identified by means of Matrix-Assisted Laser De-
sorption Ionization-Time-of-Flight Mass Spectrometry
(MALDI-TOF MS) analysis. Briefly, a random purified
colony was picked from the agar plate and spread out on
a polished steel target plate. These spots were covered
with 1.0 μL of α-cyano-4-hydroxycinnamic acid (HCCA)
matrix, according to the manufacturer’s guidelines. The
spectra were obtained and analyzed with the MBT Com-
pass software version 4.1 (Bruker Daltonik), which in-
cluded a database of 6120 mean spectra projections
(MSP). The analysis was repeated when score values <
2.000 were obtained. Genotyping of E. coli isolates was
performed using repetitive element sequenced-based
(rep)-PCR, as described by Peeters et al. [45].
MIC determination
Purified and identified E. coli isolates were subjected to
determination of the minimal inhibitory concentration
(MIC) of ENR by use of a commercial gradient strip test
(Liofilchem s.r.l., Roseto degli Abruzzi, Italy). E. coli
ATCC® 25,922™ was used as quality control strain. The
applied procedure was in accordance with the manufac-
turer’s instructions [46]. A 0.5 McFarland turbidity sus-
pension was obtained, measured by optical density, by
adding two or three well-separated colonies from a sin-
gle isolate to a glass tube containing 3.0 mL of sterile
PBS. A homogenous bacterial lawn was applied on
commercially available Mueller-Hinton (MH) agar plates
(Thermo Fisher Scientific, Breda, The Netherlands), by
spreading the suspension with a sterile cotton swab (±
100 μL). Finally, the gradient strip tests were placed in
the center of the plate. All plates were incubated aerob-
ically at 35 ± 2 °C for at least 18 h before interpretation
of the test strips. The results of the gradient strip tests
were evaluated visually, by examining the intersection of
growth reduction and the gradient strip. The concentra-
tion mark coinciding with this intersection was read as
the MIC of ENR for the specific strain.
Characterization of FQ resistance regions
Mutations in the QRDRs are the primary source of re-
sistance against FQs [47]. These QRDRs relate to spe-
cific sites on the bacterial DNA, coding for DNA gyrase
and topoisomerase IV [48]. Since amino-acid substitu-
tions in gyrA-parC occur most frequently, mutations in
gyrA-parC were investigated as resistance markers in
this study [49]. ,Additionally, the presence of plasmid-
mediated resistance via resistance genes qnrS, qnrA or
qnrB was assessed [50] by qualitative screening with gel-
electrophoresis after PCR analysis. Randomly selected
wild-type and non-wild type isolates, collected from the
fecal samples, were subjected to PCR characterization
(n = 17). The protocols and primers used for PCR have
been described previously by Chantziaras et al. [51].
Briefly, a MasterCycler Gradient EPS-S Thermal Cycler
(Eppendorf AG, Hamburg, Germany) was used for amp-
lification of the genes. After matching with the gyrA [52]
and parC [53] reference sequences of E.coli K12
MG1655 [54], all obtained amplicons were sequenced
(Eurofins Genomics GmbH, Ebersberg, Germany) and
further investigated for point mutations via BioNumerics
7 software (Applied Maths NV, Sint-Martens-Latem,
Belgium) and BioEdit 7 multiple alignment tool (Tom
Hall, Ibis Therapeutics, Carslbad, USA).
Pharmacokinetic analysis
Phoenix® WinNonlin® 6.3 (Pharsight-Certara, Prince-
ton, NJ, USA) was used for the pharmacokinetic (PK)
analysis of the data. Non-compartmental (NCA) data
analysis was performed and following PK parameters
(relevant to the pharmacodynamics properties of
ENR) were calculated: area under the 24 h-time curve
(AUC0–24h), area under the 58 h-time-curve (AUC0–
58h), AUC0–58h normalized for dose (AUC0–58h/D),
maximal plasma or fecal concentrations of ENR
(Cmax), time of maximal concentration (Tmax), steady
state plasma or fecal concentrations of ENR (Css).
The AUC values were determined using the linear
up-log down trapezoidal method.
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PK/PD analysis
The collected data from the in vitro tests was linked to
the in vivo PK data (AUC per dosing interval 0–24 h,
Cmax) with following calculated PK/PD parameters;
Cmax/MIC and AUC0–24h/MIC (h).
Statistical analysis
Plasma, intestinal and fecal ENR concentrations of the
four different groups were compared on the different
time points using a single-factor analysis of variance
(ANOVA) with SPSS 25.0 (IBM, Chicago, IL, USA).
Transformation of data (logarithmic or square root) was
occasionally applied to achieve the normality assump-
tion. A post-hoc Tukey test was performed to assess the
differences between each of the four treatment groups
(significance level p < 0.05). When equal variances were
not assumed, a post-hoc Games-Howell test was per-
formed (significance level p < 0.05). No animals were ex-
cluded from data analysis.
Supplementary information
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